1. Home
  2. SMID vs LCTX Comparison

SMID vs LCTX Comparison

Compare SMID & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith-Midland Corporation

SMID

Smith-Midland Corporation

HOLD

Current Price

$36.44

Market Cap

182.7M

Sector

Industrials

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.66

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMID
LCTX
Founded
1960
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Building Materials
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.7M
407.7M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
SMID
LCTX
Price
$36.44
$1.66
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.25
AVG Volume (30 Days)
8.8K
1.2M
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
81.92
N/A
EPS
2.22
N/A
Revenue
$88,866,000.00
$10,816,000.00
Revenue This Year
N/A
$6.32
Revenue Next Year
N/A
$124.49
P/E Ratio
$16.38
N/A
Revenue Growth
16.37
24.05
52 Week Low
$25.13
$0.37
52 Week High
$46.50
$2.09

Technical Indicators

Market Signals
Indicator
SMID
LCTX
Relative Strength Index (RSI) 58.75 46.04
Support Level $34.84 $1.58
Resistance Level $36.15 $1.77
Average True Range (ATR) 1.62 0.08
MACD 0.28 -0.01
Stochastic Oscillator 66.67 32.65

Price Performance

Historical Comparison
SMID
LCTX

About SMID Smith-Midland Corporation

Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: